OncoResponse

Seattle, United States

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

$14.0M raised

May 2023

Series D

Top Investors

Rice UniversityRedmile GroupARCH Venture PartnersGreatPoint VenturesCanaan Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has OncoResponse raised?

OncoResponse has raised $14.0M in total funding. The most recent round was Series D. The last funding was announced in May 2023.

Who are OncoResponse's investors?

OncoResponse's investors include Rice University, Redmile Group, ARCH Venture Partners, GreatPoint Ventures, Canaan Partners.

Where is OncoResponse headquartered?

OncoResponse is headquartered in Seattle, United States.

What does OncoResponse do?

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

What stage is OncoResponse at?

OncoResponse is at the Series D stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 18, 2023.

MLA

"OncoResponse — Funding & Investors." VCBacked, May 18, 2023, https://www.vcbacked.co/company/oncoresponse. Accessed June 4, 2026.

APA

VCBacked. (2023). OncoResponse — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/oncoresponse

Wikipedia (cite web)

{{cite web |title=OncoResponse — Funding & Investors |url=https://www.vcbacked.co/company/oncoresponse |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 18, 2023.